[go: up one dir, main page]

MX2018001355A - Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones. - Google Patents

Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.

Info

Publication number
MX2018001355A
MX2018001355A MX2018001355A MX2018001355A MX2018001355A MX 2018001355 A MX2018001355 A MX 2018001355A MX 2018001355 A MX2018001355 A MX 2018001355A MX 2018001355 A MX2018001355 A MX 2018001355A MX 2018001355 A MX2018001355 A MX 2018001355A
Authority
MX
Mexico
Prior art keywords
acetamide
oxo
phenyl
methyl
treatment
Prior art date
Application number
MX2018001355A
Other languages
English (en)
Other versions
MX375860B (es
Inventor
Kalvins Ivars
Misane Ilga
Cernobrovijs Aleksandrs
Stonans Ilmars
Veinbergs Grigorijs
Zvejniece Liga
Vorona Maksims
Dambrova Maija
SVALBE Baiba
Vavers Edijs
Original Assignee
Latvian Inst Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Inst Organic Synthesis filed Critical Latvian Inst Organic Synthesis
Publication of MX2018001355A publication Critical patent/MX2018001355A/es
Publication of MX375860B publication Critical patent/MX375860B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Uso de 2-(5 S-Metil-2-oxo-4R-fenil-pirrolidin-1-il)-acetamida (I) o una sal farmacéuticamente aceptable en la manufactura de un medicamento para profilaxis y tratamiento de convulsiones.
MX2018001355A 2015-08-03 2016-08-02 Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones. MX375860B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179448.4A EP3127539A1 (en) 2015-08-03 2015-08-03 Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
PCT/IB2016/054641 WO2017021881A1 (en) 2015-08-03 2016-08-02 Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures

Publications (2)

Publication Number Publication Date
MX2018001355A true MX2018001355A (es) 2018-05-22
MX375860B MX375860B (es) 2025-03-07

Family

ID=53776429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001355A MX375860B (es) 2015-08-03 2016-08-02 Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.

Country Status (11)

Country Link
US (1) US10105348B2 (es)
EP (2) EP3127539A1 (es)
JP (1) JP6470870B2 (es)
CN (1) CN107921019B (es)
BR (1) BR112018002138A2 (es)
CA (1) CA2988045A1 (es)
EA (1) EA036085B1 (es)
MX (1) MX375860B (es)
TW (1) TWI643617B (es)
UA (1) UA120886C2 (es)
WO (1) WO2017021881A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025529136A (ja) * 2022-08-31 2025-09-04 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション キラルガンマラクタム誘導体またはその薬学的に許容可能な塩およびその製造方法
CN119280228B (zh) * 2024-11-06 2025-09-19 桂林医学院附属医院 帕金森病神经保护作用药物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
PL2358360T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
LV14346B (lv) 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Also Published As

Publication number Publication date
EP3127539A1 (en) 2017-02-08
TW201709908A (zh) 2017-03-16
UA120886C2 (uk) 2020-02-25
CA2988045A1 (en) 2017-02-09
JP6470870B2 (ja) 2019-02-13
CN107921019A (zh) 2018-04-17
MX375860B (es) 2025-03-07
JP2018522019A (ja) 2018-08-09
EP3331523B1 (en) 2021-10-13
TWI643617B (zh) 2018-12-11
EA036085B1 (ru) 2020-09-24
CN107921019B (zh) 2021-03-05
BR112018002138A2 (pt) 2018-09-11
EP3331523A1 (en) 2018-06-13
WO2017021881A1 (en) 2017-02-09
EA201890122A1 (ru) 2018-05-31
US20180200227A1 (en) 2018-07-19
US10105348B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2017009449A (es) Inhibidor jak.
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX383499B (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX2017013797A (es) Inhibidor de janus quinasa.
AR103680A1 (es) Inhibidores selectivos de bace1
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2016016534A (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
CL2018001830A1 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
MX394213B (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.

Legal Events

Date Code Title Description
FG Grant or registration